Practical and Theoretical Radiotherapy Physics Courses
Course overview
This course provides practical and theoretical education for the support of a modern radiotherapy physics service within radiotherapy.
It is aimed primarily at recently qualified radiotherapy physicists, but should also be invaluable to post-graduate students, researchers, clinical oncologists, engineers, radiographers, manufacturers’ representatives and in fact, anyone needing to deepen or update their understanding of this rapidly evolving field.
The faculty is composed of physicists, clinicians and radiographers, many of whom are internationally renowned for their expertise. Workshops and demonstrations make full use of the facilities of the Radiotherapy and Physics Departments of The Royal Marsden NHS Foundation Trust. The course content is reviewed annually to reflect changes in practice and technology.
Course details
4-8 March 2025: the course in radiotherapy in March will be held at our Chelsea site.
Course fees
The cost for one week is £800.00. For those wishing to book the complete two weeks, the cost is discounted to £1,350.
External, full-time PhD students with proof of academic registration can book the eight lecture days of both weeks for a total of £700.
For registration details you can email our course secretary.
Contacts
Further details on course content can be obtained from the course organisers:
Tel: +44 (0)20 7808 2506
Fax: +44 (0)20 7808 2522
Tel: +44 (0)20 8661 3475
Fax: +44 (0)20 8643 3812
Latest ICR News
Precision oncology company Sentinal4D completes pre-seed funding round and launches to the public
Sentinal4D, a spinout company from The Institute of Cancer Research, London, has been announced to the public – having closed of its first round of funding and appointed its foundational leadership team.
Stars bring Christmas cheer to Carols from Chelsea
Christmas arrived in style as celebrities and guests got into the festive spirit at Carols from Chelsea – raising more than £125,000 for The Institute of Cancer Research, London
Major trial shows prolonged benefit of olaparib in early-stage inherited breast cancer
One year of treatment with the targeted drug olaparib improves long-term survival in women with high-risk, early-stage breast cancer with mutations in BRCA1 or BRCA2 genes, new results from a major clinical trial show.
New understanding of aggressive form of breast cancer paves the way for tests and treatments
Scientists have developed a machine learning tool that can predict how an aggressive type of breast cancer will respond to treatment, and when it will return.